Deepak Bhatt, MD, MPH, MBA, spoke to Cardiovascular Business about the growing importance of evaluating coronary inflammation in heart patients. There has been an explosion of interest in this area since the FDA's 2023 clearance of colchicine.
Hadley Wilson, MD, spoke to Cardiovascular Business at the three-day event to discuss key late-breaking studies and trends. Topics included new drug treatments, AI and much more.
Gilbert Tang, MD, spoke to Cardiovascular Business about late-breaking data from the TRILUMINATE IDE trial. While early results were promising, these latest findings highlight the TriClip device's true value for the first time.
TAVR patients presenting with peripheral artery disease face significantly higher in-hospital risks, according to a new study published in Current Problems in Cardiology.
Samir Kapadia, MD, chair of the department of cardiovascular medicine at Cleveland Clinic, shared his perspective on the use of cerebral protection devices during TAVR procedures.
“Before we examined the data, I thought we would find an ample amount of the symptoms to be specifically associated with long COVID, but that wasn’t the case," one researcher said.
While a previous study had found that extracorporeal CPR outperformed conventional CPR among patients with out-of-hospital cardiac arrest, a newer analysis suggests the two treatment options result in similar outcomes.
The device, designed to be worn for up to 24 hours at a time, uses ultrasound technology and artificial intelligence to track how much blood the user's heart is pumping.
Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.
